Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

David Ricks “We have said it’s not for us right now,” said Ricks. Reuters noted that Ricks is much bolder than his predecessors in terms of acquisitions, after years when Lilly tried to make ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

“While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter,” David ...

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...